Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel small molecule antiviral therapeutics for serious and chronic viral diseases caused by RNA viruses. Using proprietary structure-based drug design, X-ray crystallography, and computational chemistry guided by Nobel Prize-winning expertise, the company develops candidates targeting influenza virus, norovirus, coronaviruses (SARS-CoV-2, MERS-CoV), and hepatitis C virus (HCV), with lead programs including CC-42344 for influenza A.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-013838 | EDGAR | 53K words |
| 2025-03-31 | 2024-12-31 | 0001641172-25-001496 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001493152-24-011613 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001493152-23-009385 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001493152-22-007551 | EDGAR | — |
| 2021-03-17 | 2020-12-31 | 0001493152-21-006211 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001493152-20-004916 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004386 | EDGAR | — |
| 2018-03-21 | 2017-12-31 | 0001493152-18-003708 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001493152-17-003110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-022581 | EDGAR | 16K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-023728 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010539 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001493152-24-044978 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-031877 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001493152-24-018787 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040322 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028046 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-016927 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-031622 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022597 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001493152-22-012782 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001493152-26-014819 | EDGAR | 1K words |
| 2026-03-31 | 0001493152-26-013837 | EDGAR | — |
| 2026-03-13 | 0001493152-26-010071 | EDGAR | — |
| 2026-03-09 | 0001493152-26-009309 | EDGAR | — |
| 2026-02-19 | 0001493152-26-007430 | EDGAR | — |
| 2026-01-15 | 0001493152-26-002422 | EDGAR | — |
| 2025-12-18 | 0001493152-25-028296 | EDGAR | — |
| 2025-12-01 | 0001493152-25-025568 | EDGAR | — |
| 2025-11-14 | 0001493152-25-022603 | EDGAR | — |
| 2025-10-30 | 0001493152-25-020143 | EDGAR | — |
351 total filings indexed. 319 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001412486 |
| Ticker | COCP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cocrystalpharma.com |
| Listed | 2008-04-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report